Structure Therapeutics Inc.
GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus anā¦ read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$66.98
Price+1.10%
$0.73
1Y
Price
Market Cap
$3.856b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$210.685m
-71.9%
1y CAGR-61.1%
3y CAGR-52.9%
5y CAGREPS
-$3.63
-55.1%
1y CAGR-40.1%
3y CAGR-35.0%
5y CAGRBook Value
$770.019m
$832.159m
Assets$62.140m
Liabilities$7.090m
DebtDebt to Assets
0.9%
-
Debt to EBITDAFree Cash Flow
-$196.384m
-66.5%
1y CAGR-62.5%
3y CAGR-56.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company